'Latuda (lurasidone),' a medication used to treat schizophrenia and imported and distributed by Bukwang Pharmaceutical, and 'Dupixent (dupilumab),' which aims to expand reimbursement for young children, have entered negotiations with the National Health Insurance Service (NHIS).

When an agreement with the National Health Insurance Service (NHIS) is completed, reimbursement coverage is possible following reporting to the Health Insurance Policy Review Committee

According to the NHIS on June 5, Latuda 20, 40, 60, 80, 120mg and Dupixent Prefilled Inj 200 mg and 300 mg entered negotiations this month. These two drugs have cleared the review by the Drug Reimbursement Evaluation Committee (DRE